Related Experiment Video
Updated: Jul 9, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Acute lymphoblastic leukemia during gestation.
Charis Matsouka1, Spyridon Marinopoulos, Despina Barbaroussi
1Alexandra General Hospital, V Sofias and Lourou 1, 11528 Athens, Greece. charma@hol.gr
Medical Oncology (Northwood, London, England)
|November 28, 2007
Summary
Aggressive chemotherapy can effectively manage acute lymphoblastic leukemia in pregnant patients, achieving remission without harming the fetus. This approach offers a viable treatment option for this challenging condition.
Area of Science:
- Oncology
- Maternal-Fetal Medicine
Background:
- Acute lymphoblastic leukemia (ALL) in pregnancy presents complex management challenges.
- Historically, treatment strategies for pregnant ALL patients have been debated, with a global trend towards aggressive chemotherapy.
Observation:
- A case study of a young pregnant patient diagnosed with acute lymphoblastic leukemia.
- The patient was treated using an aggressive chemotherapy regimen.
Findings:
- Complete remission of acute lymphoblastic leukemia was achieved in the patient.
- The aggressive chemotherapy regimen did not adversely affect fetal development or health.
Implications:
- Aggressive chemotherapy is a feasible and effective treatment for acute lymphoblastic leukemia during pregnancy.
- This case supports the current practice trend and offers a potential management pathway for similar cases.
- Further discussion on management options is warranted to refine treatment protocols.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...